Siga Technologies Inc is a biotechnology company focused on developing solutions for public health threats, particularly through its innovative antiviral therapeutics. The company's primary emphasis is on the advancement of treatments for viral infections, with a notable concentration on smallpox and other serious infectious diseases. By leveraging its proprietary technologies, Siga aims to address unmet medical needs and improve health outcomes, especially in the face of potential bioterrorism threats or emerging viral outbreaks. Through collaborations with government entities and investment in research, the company endeavors to enhance global health security and preparedness through effective medical interventions.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CSX Corporation (NASDAQ: CSX), Stride, Inc. (NYSE: LRN), and SIGA Technologies, Inc. (NASDAQ: SIGA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA). The investigation concerns whether SIGA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
SIGA Technologies secures a $9 million DoD contract for TPOXX, boosting total outstanding orders to $154 million. Recent BARDA and DoD wins reinforce growth despite challenges in a key mpox trial.
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.
Russell 2000 ETF (ARCA: IWM) up 2.7%, its strongest session in a month, driven by positive economic data & increased consumer spending, boosting confidence in US economy.
"NIH's NIAID reveals results from the PALM 007 trial of SIGA Technologies' Tpoxx for monkeypox (mpox) treatment. The study missed its primary endpoint but showed potential benefits in early and severe cases. Learn more about the safety profile and market impact on SIGA stock.
PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases. Customers are increasingly seeking antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are easy to administer and have a shorter treatment duration. The Antiviral Drugs segment is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs. A report from Statista said that: “The projected revenue in the Antiviral Drugs market worldwide is estimated to reach US$51.18bn in 2024. It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.58%, leading to a market volume of US$55.36bn by 2029. In terms of global comparison, United States is anticipated to generate the highest revenue, with US$30,640.00m in 2024. In the worldwide market for antiviral drugs, the United States leads in research and development, driving innovation and setting industry standards.” Active Biotechs in the biotech markets today include: NanoViricides, Inc. (NYSE: NNVC), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Veru Inc. (NASDAQ: VERU), Chimerix (NASDAQ: CMRX), SIGA Technologies, Inc. (NASDAQ: SIGA).
